Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis

Lucijanić, Marko; Veletić, Ivo; Rahelić, Dario; Pejša, Vlatko; Cicic, David; Skelin, Marko; Livun, Ana; Tupek, Katarina Marija; Štoos‐Veić, Tajana; Lucijanić, Tomo; Maglicic, Ana; Kušec, Rajko

doi:10.1007/s00508-018-1318-z

Cited by 28 publications

(21 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…PNI reflects the nutritional and immunological aspects of patients simultaneously because it is based on the peripheral lymphocyte count and serum albumin levels. [22] Studies have proven that lymphocytes and serum albumin are both independent prognostic risk factors of cancer patients. [23,24] Hypoalbuminemia or lymphocytopenia was the reason of low PNI.…”

Section: Discussionmentioning

confidence: 99%

The prognostic value of pre-treatment prognostic nutritional index in esophageal squamous cell carcinoma

Wang

Lai

et al. 2019

Medicine

View full text Add to dashboard Cite

Background: Prognostic nutritional index (PNI) is an easily obtained index inflecting both one's nutritional and inflammatory status. Its clinical role in esophageal squamous cell carcinoma (ESCC) remains still in debate. The aim of this meta-analysis was to assess the prognostic value and the clinical-pathological features of pre-treatment PNI in ESCC patients. Methods: A comprehensive search of online databases (PubMed, Embase, Web of Science) was performed. Studies explored the relationship between pre-treatment PNI and long-term survival of ESCC patients were regarded eligible for this meta-analysis. Outcomes were extracted and synthesized. Hazard ratio (HR) and relative ratio (RR) with 95% confidence interval (CI) were used to evaluate the prognostic value of PNI on long-term survival and association with clinical-pathological features, respectively. The heterogeneity levels and publication bias between studies were also estimated. Results: Nine observational studies involving 2276 patients were considered eligible for this meta-analysis. The pooled results showed that low PNI score was significantly correlated with poorer overall survival (OS) of esophageal cancer (pooled HR = 1.418 95%CI: 1.200–1.676, P = .000), poorer recurrence free survival (HR = 1.880 95%CI: 1.207–2.929, P = .005) but not cancer specific survival (CSS) (HR = 1.948 95%CI: 0.544–6.977, P = .306). The PNI value was not related with patient age, sex, depth of tumor invasion, nodular metastasis, and differential grade but the TNM stage (III/IV vs 0/I/II, RR = 1.276, 95% CI 1.146–1.420). Conclusions: Low pre-treatment PNI was significantly related with OS and recurrence free survival but not CSS for ESCC. PNI was a reliable prognostic factor of ESCC, and higher stage ESCC have higher incidence of low PNI.

show abstract

Section: Discussionmentioning

confidence: 99%

The prognostic value of pre-treatment prognostic nutritional index in esophageal squamous cell carcinoma

Wang

Lai

et al. 2019

Medicine

View full text Add to dashboard Cite

show abstract

“…In turn, these cytokines are markedly decreased by treatment with ruxolitinib, while HSA levels are increased 15,16 . Recently, HSA level has been suggested as an independent indicator for prognosis in MF patients uncorrelated with cytogenetic or mutation profiles 17,18 . HSA and serum cholesterol levels were used to develop a new cachexia index further enhancing prognostication in MF 19 .…”

Section: Introductionmentioning

confidence: 99%

Ruxolitinib binding to human serum albumin: bioinformatics, biochemical and functional characterization in JAK2V617F+ cell models

Marinis

Ceccherelli

Quattrocchi

et al. 2019

Sci Rep

View full text Add to dashboard Cite

Ruxolitinib is a type I JAK inhibitor approved by FDA for targeted therapy of Philadelphia-negative myeloproliferative neoplasms (MPNs), all characterized by mutations activating the JAK2/STAT signaling pathway. Treatment with ruxolitinib improves constitutional symptoms and splenomegaly. However, patients can become resistant to treatment and chronic therapy has only a mild effect on molecular/pathologic remissions. Drugs interaction with plasma proteins, i.e. human serum albumin (HSA), is an important factor affecting the intensity and duration of their pharmacological actions. Here, the ruxolitinib recognition by the fatty acid binding sites (FAs) 1, 6, 7, and 9 of HSA has been investigated from the bioinformatics, biochemical and/or biological viewpoints. Docking simulations indicate that ruxolitinib binds to multiple sites of HSA. Ruxolitinib binds to the FA1 and FA7 sites of HSA with high affinity (Kr = 3.1 μM and 4.6 μM, respectively, at pH 7.3 and 37.0 °C). Moreover, HSA selectively blocks, in a dose dependent manner, the cytotoxic activity of ruxolitinib in JAK2V617F+ cellular models for MPN, in vitro. Furthermore this event is accompanied by changes in the cell cycle, p27Kip1 and cyclin D3 levels, and JAK/STAT signaling. Given the high plasma concentration of HSA, ruxolitinib trapping may be relevant in vivo.

show abstract

“…These could indicate worse nutritional status or higher inflammatory atmosphere and were shown to be predictive of inferior survival in myelofibrosis independently of each other and DIPSS [34]. Thus, numerous pathophysiologic processes modulate TSAT and are reflected in its reduction.…”

Section: Discussionmentioning

confidence: 99%

Prognostic implications of low transferrin saturation in patients with primary myelofibrosis

et al. 2018

Self Cite

View full text Add to dashboard Cite

Assessing serum albumin concentration, lymphocyte count and prognostic nutritional index might improve prognostication in patients with myelofibrosis

Abstract: Assessing albumin, ALC and PNI might improve prognostication in patients with myelofibrosis and could assist in recognition of patients under increased risk of death.

Cited by 28 publications

References 33 publications

The prognostic value of pre-treatment prognostic nutritional index in esophageal squamous cell carcinoma

The prognostic value of pre-treatment prognostic nutritional index in esophageal squamous cell carcinoma

Ruxolitinib binding to human serum albumin: bioinformatics, biochemical and functional characterization in JAK2V617F+ cell models

Prognostic implications of low transferrin saturation in patients with primary myelofibrosis

Contact Info

Product

Resources

About